Compounds > cabergoline
Page last updated: 2024-08-23

cabergoline and Depressive Disorder, Major

cabergoline has been researched along with Depressive Disorder, Major in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (50.00)29.6817
2010's1 (25.00)24.3611
2020's1 (25.00)2.80

Authors

AuthorsStudies
Ciftci, S; Ersungur, EB; Gul, N; Kadioglu, P; Ozkaya, HM; Poyraz, BC; Sahin, S; Sarac, B; Sulu, C; Tanrikulu, S; Tanriover, E; Yener Ozturk, F1
Baumgarten, E; Connemann, B; Feneberg, E; Gahr, M; Merger, S; Özpeynirci, Y; Schönfeldt-Lecuona, C1
Higuchi, H; Sugawara, Y; Yoshida, K1
Davie, M1

Other Studies

4 other study(ies) available for cabergoline and Depressive Disorder, Major

ArticleYear
Risk of impulse control disorders in patients with Cushing's disease: do not blame cabergoline but do not give up caution.
    Pituitary, 2023, Volume: 26, Issue:4

    Topics: Cabergoline; Cross-Sectional Studies; Depressive Disorder, Major; Disruptive, Impulse Control, and Conduct Disorders; Humans; Pituitary ACTH Hypersecretion; Prospective Studies

2023
Prolactin serum concentrations after electroconvulsive therapy in a depressed patient with cabergoline-treated prolactinoma: implications for treatment.
    The journal of ECT, 2015, Volume: 31, Issue:2

    Topics: Antidepressive Agents; Antineoplastic Agents; Cabergoline; Depressive Disorder, Major; Electroconvulsive Therapy; Ergolines; Female; Humans; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma

2015
Dramatic remission of treatment-resistant depression after the cessation of tricyclic antidepressants.
    Pharmacopsychiatry, 2006, Volume: 39, Issue:3

    Topics: Adult; Antidepressive Agents, Tricyclic; Cabergoline; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Ergolines; Female; Fluvoxamine; Humans; Imipramine; Substance Withdrawal Syndrome; Treatment Outcome

2006
Pathological gambling associated with cabergoline therapy in a patient with a pituitary prolactinoma.
    The Journal of neuropsychiatry and clinical neurosciences, 2007,Fall, Volume: 19, Issue:4

    Topics: Antidepressive Agents; Antineoplastic Agents; Cabergoline; Citalopram; Delusions; Depressive Disorder, Major; Ergolines; Female; Gambling; Humans; Middle Aged; Pituitary Neoplasms; Prolactinoma

2007